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3,4,5-trimethoxy-e-methyl-fl-phenylethylamine; and 3,4-methylene- 
dioxy-N,e-dimethyl-fl-phenylethylamine) has been studied in the mouse, 
rat and guinea pig following ip administration and in the mongrel dog and 
rhesus monkey following iv administration. The LD50 value for each agent 
has been determined in each species. For 7 of the 8 drugs tested the LD50 
value is significantly lower in the rat than in the mouse or guinea pig. A 
comparison of the observable signs of drug action in the dog and monkey 
shows the dog to be the preferred species for evaluating the effects of these 
agents. The relevant literature regarding the actions of the drugs has been 
reviewed. Modifications in the mescaline structure which are represented 
by the 7 analogs and which alter pharmacologic activity include: decreased 
potency following removal of the 5-methoxy group or N-demethylation, and 
increased potency following alpha substitution on the side chain or introduc- 
tion of the 3,4-methylenedioxy group. 
Mescaline was one of the first drugs recognized as having hallucinogenic properties. 
Although the effects of mescaline in man have been described by many investigators 
(Stockings, 1940; Hock, 1951), the mechanisms by which mescaline alters central ner- 
vous system function are not yet clear. It has been suggested that the psychotomimetic 
action may arise owing to competition for adrenergic receptors (Ratcliffe, 1971; 
Speck, 1957), or cholinergic receptors (Clemente and Lynch, 1968), and that psycho- 
tomimetic action may result from metabolism in vivo to form an active material (Block 
et aL, 1952). 
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It is possible that some of the difficulties in comparing effects on the human central 
nervous system with data from experimental animals may be explained on the basis 
of the choice of laboratory animal model for study. In the investigation reported here, 
the toxicity of mescaline has been compared in 5 animal species in an effort to identify 
differences in species sensitivity which may be utilized for further experimental studies. 
In addition, toxicity data obtained from 7 mescaline analogs permit conclusions re- 
garding structural requirements for the toxicity of agents of this type in the 5 species 
employed. 
METHODS 
Drugs employed in this study were synthesized and supplied by the Army Chemical 
Center, Edgewood Arsenal. The structural formulas of mescaline (I) and of 7 analogs 
are shown in Fig. 1. 
FIG. 1. Structural formulas of mescaline and seven analogs. 
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Male and female animals from the following five species were used: Swiss- 
Webster mice, Upjohn (Sprague Dawley) rats, guinea pigs, mongrel dogs and 
Macaca Mulatta monkeys. Drugs were administered ip (mice, rats, guinea pigs) or iv 
(dogs, monkeys) as a single injection of the hydrochloride salt dissolved in saline 
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TABLE 1 
TOXICITY OF MESCALINE AND ANALOGS IN FIVE MAMMALIAN SPECIES 
Compound 
No. Species 
Route LD50 (mg/kg) 
of and 95 ~ LD50 (mmol/kg of Molar 
adminis- confidence base) and 95 ~o toxicity 
















































ip 40 212 (202-222) 0.86 a (0.82-0.90) 1.0 
ip 28 132 (108-161) 0.53 (0.44-0.65) 1.0 
ip 32 328 (289-373) 1.33" (1,17-1.51) 1.0 
iv 16 54 (46-64) 0.22 (0.18-0.26) 1.0 
iv 17 130 (105-161) 0.53 b (0.42-0.65) 1.0 
ip 49 363 (341-386) 1.69" (1.59-1.80) 0.51 
ip 32 146 (131-162) 0.68 (0.61-0.76) 0.78 
ip 20 375 (351-400) 1 . 7 5 4  (1.64-1.86) 0.76 
iv 16 122 (109-136) 0.57 (0.51-0.63) 0.39 
iv 9 220 (173-280) 0.98 b (0.81-1.30) 0.54 
ip 30 176 (163-190) 0.88 a (0.82-0.95) 0.98 
ip 24 55 (42-72) 0.28 (0.21-0.36) 1.89 
ip 20 245 (227-265) 1.23 a (1.14-1.32) 1.08 
iv 16 28 (25-32) 0.14 (0.12-0,16) 1.57 
iv 16 45 (40-51) 0.22 b (0.20-0,26) 2.41 
ip 92 68 (50-92) 0.32 a (0.23-0,43) 2.68 
ip 24 27 (19-40) 0.13 (0.09-0,19) 4.07 
ip 60 28 (23-45) 0.13 (0.07-0,21) 10.02 
iv 17 7 (5-10) 0.03 (0.02-0.05) 7.34 
iv 18 6 (5-9) 0.03 (0.02-0.04) 17.65 
ip 50 82 (74-91) 0.36 (0.32-0,40) 2.39 
ip 32 95 (82-108) 0.41 (0.37-0.47) 1.29 
ip 20 88 (65-119) 0.38 (0.28-0.52) 3.50 
iv 16 16 (10-26) 0.07 (0.04-0.11) 3.14 
iv 16 20 (12-33) 0.09 (0.05-0.14) 5.89 
ip 40 168 (157-180) 0.73" (0.68-0.78) 1.18 
ip 32 48 (41-57) 0.21 (0.18-0.25) 2.52 
ip 20 195 (165-230) 0.84" (0.72-1.00) 1.58 
iv 16 59 (52-67) 0.26 (0.22-0.29) 0.85 
iv 14 53 (46-61) 0.23 (0.19-0.26) 2.30 
ip 40 240 (222-259) 0.92 a (0.85-0.99) 0.93 
ip 32 149 (142-156) 0.57 (0.54-0.60) 0.93 
ip 20 172 (159-186) 0.65 a (0.61-0.71) 2.04 
iv 16 23 (18-29) 0.09 (0.07-0.11) 2.45 
iv 15 31 (25-38) 0.12 (0.10-0.15) 4.42 
ip 50 97 (89-106) 0.42" (0.39-0.46) 2.04 
ip 32 49 (46-52) 0.21 (0.20-0.23) 2.52 
ip 16 98 (88-111) 0.43 a (0.38-0.48) 3.09 
iv 16 14 (8-23) 0.06 (0.03-0.10) 3.67 
iv 26 22 (17-28) 0.09 (0.07-0.12) 5.89 
"Significantly different (p < 0.05) from the value obtained in the rat. 
b Significantly different (p < 0.05) from the value obtained in the dog. 
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LD50 values were calculated by the method of Litchfield and Wilcoxon (1949) on the 
basis of  mortality within 24 hr after drug administration. The LD50 values are expressed 
in the conventional format of mg/kg for the hydrochloride salt and as mmol/kg. The 
molar toxicity ratio (the LD50 in mmol/kg of mescaline/LD50 in mmol/kg of the 
analog) has been employed as a measure of relative potency and mescaline was assigned 
the value of 1.0. Significant differences were determined with 95 % confidence limits by 
the Range Overlap test. 
Gross observation of the physical and behavioral responses to the drugs were made 
by trained observers. 
RESULTS 
Toxicity 
The lethality of  mescaline and of 7 analogs has been determined following ip admini- 
stration to the mouse, rat and guinea pig and following iv administration to the dog and 
monkey (Table 1). To aid drug toxicity comparisons, LD50 values are expressed both as 
mg/kg and as mmol/kg. The LD50 values (mg/kg) obtained following ip administration 
show distinct differences in species sensitivity to the 8 drugs; the LD50 value is lowest 
in the rat for all compounds tested with the exception of compounds IV and V. When the 
data are expressed on a molar basis, the LD50 value in the rat is significantly lower than 
TABLE 2 
OBSERVED EFFECTS OF MESCALINE A N D  ANAOLGS IN THE UNANESTHETIZED DOG AND MONKEY a 
Compound No. 
Observations I II III  IV V VI VII VIII 
Motor activity 
Ataxia D, M D, 
Convulsions (clonic) D, M D 
Convulsions (tonic) D, M D 
Muscular rigidity D, M D, 
Muscle tremors D, M D 
Autonomic activity 
Mydriasis D, M D, 
Piloerection M M 
Salivation D, M D, 
Vascular flushing D, M D, 
CNS activity 
Emesis D D 
Apprehension or fright D, M D 
Bizarre body attitudes D D 
Hallucinations (apparent) D D 
Dyspnea D, M D, 
Hyperpnea D, M D 
M D  D M M D D , M  
D D, M M  D, M D  
D , M  D , M  D , M  D , M  D , M  D , M  
M D , M  D , M  D M M D , M  
D , M  D , M  D , M  D , M  D , M  D , M  
M D , M  D , M  D , M  D , M  D , M  D , M  
M D , M  D, M M  D 
M D D , M  D D D , M  D , M  
M 
D D D, M D ,  M D  
D D , M  D , M  D , M  D , M  D , M  
D D D 
D D, M D  D D, M D ,  M 
M D ,  M D  M D D, M M  
D D D D D, M D ,  M 
a Compounds were given iv over the following dosage range (mg/kg) to dog (D) and monkey (M): 
I, D 5-60 (N = 22), M 10-200 (N = 17); II, D 15-200 (N = 27), M 50-300 (N = 9); III, D 25-75 (N = 24), 
M 30--90 (N= 20); IV, D 0.5-15 (N= 27), M 1-20 (N= 21); V, D 5-100 (N= 17), M 20-30 (N= 16); 
VI, D 50-75 (N= 16), M 30-60 (N= 14); VII, D 15-35 (N= 16), M 25-75 (N= 19); VIII, D 5-50 
(N = 28), M 10-75 (N = 28). 
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that in the mouse or guinea pig for compounds, I, II, III ,  VI, VII and VIII. Comparison 
of the iv toxicity of 8 compounds in the dog and monkey indicates that the LD50 
values (mmol/kg) are significantly lower in the dog in the cases of  compounds I, I I  and 
III.  
Behavior 
The presence or absence of 15 signs related to motor,  autonomic and central nervous 
system function was noted. These data, summarized in Table 2, were obtained over a 
wide range of doses, and represent a qualitative response obtainable with each substance. 
Note that in relatively few cases was an effect noted in the monkey and not seen in the 
dog. The superiority of  the dog as a species for evaluating these compounds was shown 
by the fact that specific effects consistently observed with mescaline and its analogs in 
the dog but not in the monkey include: ataxia, clonic convulsions, salivation, emesis, 
apprehension or fright and apparent hallucinations. 
TABLE 3 
STRUCTURE ACTIVITY RELATIONSHIPS IN THE DOG 
LD50 (mmol/kg) and 
Compound 95 ~ confidence limits N p value 
A. Comparison of compounds having identical side 
chains, different ring structures 
III  0.14 (0.12-0.16) 16 <0.05 I 0.22 (0.18-0.26) 16 
IV 0.03 (0.02-0.05) 17 <0.05 VII 0.09 (0.07-0.11) 16 
III  0.14 (0.12-0.16) 16 <0.05 II  0.57 (0.51-0.63) 16 
IV 0.03 (0.02-0.05) 17 <0.05 
V! 0.26 (0.22-0.29) 16 
B. Comparison of compounds that differ only in the 
substituent at position number 5 
I1 0.57 (0.51-0.63) 16 <0.05 1 0.22 (0.18-0.26) 16 
V1 0.26 (0.22-0.29) 16 <0.05 VII 0.09 (0.07-0.11) 16 
C. Comparison of compounds having the same ring 
structures, different side chains 
IV 0.03 (0.02-0.05) 17 <0.05 V 0.07 (0.044).11) 16 
IV 0.03 (0.02-0.05) 17 <0.05 II1 0.14 (0.12-0.16) 16 
I1 0.57 (0.51-0.63) 16 <0.05 V1 0.26 (0.22-0.29) 16 
I 0.22 (0.18-0.26) 16 <0.05 VII 0.09 (0.07-0.11) 16 
III  0.14 (0.12-0.16) 16 <0.05 V 0.07 (0.14-0.11) 16 
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The classical pharmacologic response to iv mescaline in the dog is characterized by 
an immediate hind limb weakness accompanied by a fluttering motion of the hind leg 
so that the dog is forced to assume a sitting position. Salivation, gagging, emesis and 
defecation are frequent sequelae to the initial motor effects. The dog may then appear 
negativistic and assume bizarre body attitudes with the head and neck arched toward 
the floor and the front legs spread widely apart. During this period, which may last for 
several hours, the dog shows minimal reaction to loud noises or noxious stimuli. 
Subsequently, the dog appears to be weak and sleepy; however, when forcefully 
aroused he exhibits a pronounced hind limb ataxia. With adequate doses the initial 
motor effect on the hind limb consisting of overt tremors is followed by tonic and clonic 
convulsions. The convulsive episodes are preceded and followed by barking, yelping 
and apparent hallucinations. The dog usually exhibits marked mydriasis and runs 
wildly about the room bumping into walls and furniture. The dog also appears to be 
apprehensive, frightened and disoriented; barking or snarling at inanimate objects 
is noted frequently. The 7 analogs of mescaline produce similar qualitative effects in the 
dog with adequate doses. 
Structure-Activity Relationships 
The toxicity of each analog has been compared to that of mescaline in each of the 5 
species. It can be seen that the analogs differ greatly in toxicity, and range from approxi- 
mately 0.5 (compound II in the mouse) to 17 times (compound IV in the monkey) as 
potent as mescaline. The data indicate that compound II in general is the least potent 
agent in this series of substances, and that compound IV is the most potent. The relation- 
ships between structure and lethality are shown more clearly in Table 3, which sum- 
marizes the influence of structural alterations on the LD50 value in the dog. The data 
suggest that the presence of the methylenedioxy substituent (Table 3,A) and of the 
methoxy group at position number 5 (Table 3, A) results in increased toxicity to the dog. 
DISCUSSION 
Mescaline (I) (3,4,5-trimethoxy-fl-phenylethylamine) is the primary hallucinogenic 
alkaloid of peyote. The pharmacology of mescaline in man and in laboratory animals 
has been reviewed recently (Kapadia and Fayex, 1970) and consequently will not be 
discussed in detail here. 
Five of the 7 mescaline analogs evaluated in this study have been investigated in 
other laboratories. Compound II (3,4-dimethoxy-/%phenylethylamine) was synthesized 
by Skita and Keil (1932) and recently has been shown to be a naturally occurring 
alkaloid of peyote (Lundstrom and Agurell, 1968). Its pharmacologic activity in the 
mouse was examined by Epstein et al. (1932), who found it to be a central nervous system 
depressant devoid of peripheral sympathomimetic activity. The effects of compound 
II on the central nervous system include alteration of conditioned and escape behavior 
(Smythies and Levy, 1960; Smythies and Sykes, 1966; Levis and Caldwell, 1971), 
excitation of the limbic system and/or inhibition of the neocortex (Bridger and Mandel, 
1967) and behavioral changes in the rat following intrastriatal administration (Little 
et al., 1968; Dill et al., 1969). Urinary excretion of compound II by schizophrenic 
patients was reported by Friedhoff and van Winkle (1962) and has been confirmed by 
several laboratories. Gunn et al. (1939) reported a positive inotropic and chronotropic 
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response to compound II in the isolated perfused cat heart, but were unable to repro- 
duce these results in the isolated perfused rabbit heart. In view of the discrepancies 
in the results obtained in these two preparations, the authors suggested that rodents 
may be less susceptible to certain actions of this substance than are other species. 
Compound III (3,4-methylenedioxy-fi-phenylethylamine) was classified by Epstein 
et al. (1932) as a central nervous system stimulant which produces convulsions in mice. 
Peripheral sympathomimetic action was observed in cats but not in rodents. Gunn et al. 
(1939) found this substance to have greater pressor activity in the decerebrate cat than 
did compound II. 
Compound IV (3,4-methylenedioxy-~-methyl-fl-phenylethylamine) has been re- 
ported by Gunn et al. (1939) to be a more powerful central nervous system stimulant 
in cats, rabbits and mice than is DE-amphetamine. These investigators also reported 
that compound VI (3,4-dimethoxy-~-methyl-fl-phenylethylamine) produced slight 
tremors and ataxia without marked stimulant effect in mice. 
Hey (1947) synthesized compound VII (3,4,5-trimethoxy-~-methyl-fl-phenylethyl- 
amine) and was impressed by the euphoria that resulted from self-administration. 
Peretz et al. (1955) administered this substance to dogs by rapid iv infusion and noted 
an acute catatonic reaction of several hours' duration. Oral administration to man 
(0.88-2.0 mg/kg) produced nausea, increased motor activity, giddiness, a decrease in 
inhibitions, increased communicativeness, lack of coordination, bilateral hyper- 
reflexia of the deep tendons, a slight increase in heart rate and hallucinations. 
A variety of additional actions of these mescaline analogs have been reported to 
occur in vivo (Epstein et al., 1932; Gunn et al., 1939; Loman et al., 1941 ; Hyde et al., 
1949) and in vitro (Epstein et al., 1932; Gunn et al., 1939; Mann and Quastel, 1940; 
Ota, 1948; Ellis, 1949). 
The effects of mescaline on a variety of organ systems, both in vivo and in vitro have 
been described in several species, but toxicity information has been minimal. A variety 
of mescaline salts exists; these salts differ in molecular weight and in molar content of 
mescaline base. Consequently, data obtained with the various salts must be compared 
on the basis of the millimolar content of mescaline base. Speck (1957) reported the 
LD50 value of mescaline sulfate in the rat to be 370 mg/kg when administered ip, 
This value is equivalent to 1.32 mmol mescaline base/kg, and differs markedly from the 
value of 0.53 mmol/kg obtained with mescaline hydrochloride and reported in Table 1. 
Delay et al. (1950) reported the LD50 of mescaline sulfate in the mouse to be 177.5 
mg/kg when administered iv. This value is equivalent to 0.65 mmol mescaline base/kg, 
and is of the same order of magnitude as the value of 0.86 mmol/kg (Table 1) obtained 
with mescaline hydrochloride administered ip. 
In the present investigation, ip LD50 values for mescaline hydrochloride have been 
obtained in the rat, mouse and guinea pig and are reported to be 123, 220 and 370 
mg/kg, respectively. These studies show a significant difference in the toxicity of mesca- 
line in the rat as compared with the mouse or guinea pig. A comparison of relative 
lethality shows the rat to be approximately twice as sensitive to the lethal effect of 
mescaline as is the mouse or the guinea pig. 
In view of the widespread acceptance of the concept that the monkey is the species 
of choice for evaluating agents which are hallucinogenic in man, the effects of mescaline 
hydrochloride in the dog and monkey also were compared. The toxicity data (Table 1) 
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indicate that the dog is the more sensitive species (iv LD50 values are 0.22 and 0.53 
mmol/kg for the dog and monkey, respectively). 
The relationship between chemical structure and pharmacological activity of 
psychoactive agents is an area of considerable interest. In the present study information 
is presented regarding the toxicity of 7 mescaline analogs in 5 animal species. A compari- 
son of the LD50 (mmol/kg) values obtained for each analog in the species tested shows 
that, as is the case with mescaline, the rat is in most cases more sensitive to the toxic 
effects of the agent than are the mouse and guinea pig. Exceptions to this generalization 
are seen with compounds IV and V, and cannot as yet be explained. 
The behavioral responses of the dog and monkey to mescaline and the 7 derivatives 
tested, show many similarities. Quantitative and perhaps qualitative differences exist, 
however, since only 3 of the 8 substances tested produced apparent hallucinations in the 
monkey whereas all the compounds appeared to be hallucinogenic in the dog (Table 2). 
Note that hallucinatory behavior was not observed in the monkey with mescaline (I) 
even though iv doses up to 200 mg/kg were administered. 
It is our impression that the dog is superior to the monkey as an experimental subject 
for predicting psychotomimetic responses characteristic of the mescaline-type drugs. 
The dog is also more sensitive than the monkey to other pharmacologic and toxicologic 
effects of mescaline and its analogs, as is illustrated in Tables 1 and 2. Note that the 
LD50 values for the compounds are lower in the dog than in the monkey. There may 
be some advantages to using dogs for screening substances for psychotomimetic 
activity. Most investigators have more experience in recognizing normal and abnormal 
behavior in dogs than in monkeys. The monkey frequently exhibits stoic behavior in 
response to stress and he may successfully conceal his anxiety and altered perceptions. 
The effects of mescaline in man have been described by many investigators. Stockings 
(1940), who was among the first to describe in detail these effects, reported the following 
signs and symptoms after oral administration of 200-500 mg mescaline: mydriasis, 
conjunctival injection, flushing, mild tremor and incoordination, impaired pain sensa- 
tion, augmentation of all deep reflexes, hyperpnea, nausea and vomiting, loss of spatial 
discrimination and exaggerated or prolonged after images, as well as delusions, hallu- 
cinations and various other psychic disturbances. All the objective signs, as well as 
some of the subjective signs described, are discernible following iv administration of 
mescaline to the dog. However, the dog may require 2-4 times as much of the substance 
as man to elicit a comparable response. At high doses all dogs exhibited the above effects, 
at lower doses the percent of animals showing these effects varied directly with the dose. 
In  the doses used, the effects of mescaline in the dog were sufficiently pronounced as to 
be apparent to several observers, whereas the effects on the monkey were interpreted 
only by trained observers. The signs reported here to be produced in the dog by mescaline 
are qualitatively similar to those reported previously by Cochin et al. (1951). No de- 
tailed analysis of the effects of mescaline or analogs has been reported until now in the 
monkey. 
The extensive data contained in this report provide a base for further studies in man. 
A comparison of the observed effects of mescaline and its analogs reported in Table 2 
for the dog and monkey with similar studies in man will provide an answer as to the 
relative value of the dog and monkey as experimental animals for predicting the CNS 
effects of mescaline-type substances in man. 
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The structure-activity relationship of substituted phenylethylamines has been dis- 
cussed in detail in several recent reviews (Kapadia and Fayez, 1970; Shulgin, 1970; 
Brawley and DuMeld, 1972). The compounds studied contain one or more of the follow- 
ing types of structural modifications: (1) addition ofmethoxy groups at various positions 
on the benzene ring, (2) introduction of the methylenedioxy group at ring positions 
3-4, or (3) variations in the length and branching of the side chain. Shulgin et al. (1961) 
had proposed the "mescaline unit" (ED mescatine/ED analog) as a measure of relative 
potency of mescaline analogs. In this calculation, the effective dose represents the arith- 
metic mean of the ED1 and ED100 values for the free base. In the data reported here a 
similar calculation, based on the ratio of LD50 values, has been carried out and is 
expressed as the "molar toxicity ratio." On the basis of these and other comparisons, 
several conclusions appear justified regarding the relationship between structure and 
potency: 
1. Removal of the 5-methoxy group from mescaline results in a less potent agent. 
Smythies and Levy (1960) found compound II to be one-half as potent as mescaline 
(I) in the rat rope-climbing assay. This difference in potency has been confirmed in the 
present study. On the basis of LD50 determinations the potency of compound II has 
been shown to vary from about 0.4 to 0.08 that of mescaline in the 5 species tested. 
In addition, a comparison of the toxicity of compound I versus II and compound VII 
versus VI in the dog (see Table 3, B) shows the drugs containing the 5-methoxy sub- 
stituent (I and VII) to be significantly more potent than those without it (II and VI). 
2. N-methylation of mescaline decreases central nervous system potency. The 
N,N-dimethyl analog of mescaline has been found to be less potent than mescaline in 
man (Luduena, 1936) and in rats (Smythies and Sykes, 1966). The studies reported here, 
in which the N-monomethyl analog of mescaline was employed, support this conclusion. 
A comparison of the LD50 values (mmol/kg) for compounds IV and VIII shows that 
in each species the N-methyl analog (VIII) is less toxic. 
3. Alpha substitution on the side chain may alter activity of the drugs in this series. 
Peretz et al. (1955) reported the hallucinogenic potency of 3,4,5-trimethoxyampheta- 
mine (VII) in man to be similar to that of mescaline, whereas Shulgin (1964) reported 
it to be less potent than mescaline and qualitatively different. In the studies reported 
here the effect of alpha-methyl substitution on potency can be seen by comparing 
the LD50 (mmol/kg) values of compounds II versus VI and compound I versus VII 
in each species. The data show compound II to be less potent than the corresponding 
alpha-methylmescaline (VI) in each species tested (Table 1). Mescaline (I) also is less 
potent than alpha-methylmescaline (VII) in the guinea pig, dog and monkey (Table 1). 
When the LD50 values for these drugs are compared in the dog, it can be seen that these 
differences in potency are significant (Table 3, C). A comparison of the corresponding 
methylenedioxy analogs (III versus IV) also shows that the alpha-substituted compound 
is more potent (Table 3, C). 
The conclusion appears justified that, in the dog, the presence of a methyl or ethyl 
substitution in the alpha position of the side chain significantly increases toxicity. 
This can be seen by comparing the LD50 values for compound IV versus V, compound 
III versus IV, compound I versus VII, and compound II versus VI, as presented in 
Table 3, C. 
4. Introduction of the 3,4-methylenedioxy group alters potency. Shulgin (1964) 
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compared the potency of compound VII to that of the corresponding 3,4-methylene- 
dioxy compound in man, and found that the methylenedioxy group increased potency 
to about 3 times that of mescaline. This conclusion is supported in part by the data 
presented in Table 1 and Table 3. A comparison of the phenylisopropylamine compound 
(VI) and its corresponding methytenedioxy analog (IV) shows the LD50 of compound 
IV to be lower in all 5 species (Table 1). However, in the phenylethylamine series, com- 
pound III is not consistently more potent than II (Table 1). A comparison of the potency 
of compound II versus III and compound VI versus IV in the dog (Table 3, A) shows a 
significant increase in potency in both methylenedioxy compounds (III and IV) as 
compared to the corresponding 3,4-dimethoxy analogs (II and VI). 
The data now available relating toxicity and pharmacologic activity to the structure 
of mescaline and its congeners are still inadequate since they do not permit satisfactory 
prediction of the pharmacologic actions of these agents in man. Such prediction is 
dependent upon the correlation of information regarding the psychotomimetic activity 
in man with the effects of these and other agents on the biochemical and behavioral 
patterns of experimental animals. It has been suggested (Snyder and Richelson, 1968) 
that psychotomimetic potency in man may be predicted on the basis of chemical con- 
formation, but the reliability of this concept alone in predicting the potency of mescaline 
analogs appears questionable (Brawley and Duffield, 1972). The problem of predicting 
activity is further complicated by the inconclusive information regarding the metabolism 
of mescaline and analogs in various species, and by the meager information concerning 
the biochemical effects produced by these agents in the central nervous system. 
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